6519 ORAL Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer.

Details

Language :

English

ISSN :

13596349

Volume :

5

Issue :

4

Database :

Supplemental Index

Journal :

EJC Supplements

Publication Type :

Academic Journal

Accession number :

27457447

Full Text :

https://doi.org/10.1016/S1359-6349(07)71347-2